In recent years, a large number of studies have increasingly linked ADAR1 to cancer progression, and major pro‐oncogenic effects are being seen in a growing number of cancer types, including hepatocellular carcinoma [78], lung cancer [79, 80], breast cancer [81, 82, 83], gastric cancer [84], cervical cancer [85], colorectal cancer [86, 87], thyroid cancer [88, 89], and glioblastoma (GBM) [90, 91]. Here, ADAR is linked to glioblastoma.